Full Text
Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Abstract

Value in Health. 2019; 22(2):168-176.

DOI of original article: 10.1016/j.jval.2018.08.011

In the original published version of this article, Figure 1 on page 169 appeared incorrectly. The figure is shown correctly below:

Opens large image

EDDS indicates Kurtzke Expanded Disability Status Scale.

Authors

Back to Volume 22, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×